Hematological response to quercetin treatment in patients with FA with evidence of marrow failure at baseline
| Patients . | Marrow failure status at baseline . | Hematological response . | ANC response . | Hb response . | Platelet response . | Time of response . | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Mild | - | - | Yes | √ | - | - | 8 wk, 6 mo |
| 2 | - | - | Severe | Yes | √ | - | - | 2 and 8 wk, 4 mo |
| 3 | - | Moderate | - | Yes | √ | - | - | 2 and 8 wk, 4 mo |
| 4 | - | - | Severe | Yes | √ | - | - | 8 wk, 6 mo |
| 5 | Mild | - | - | Yes | - | - | √ | 4, 8, and 14 wk, 4, 6, and 9 mo, 1 y |
| 6 | Mild | - | - | Yes | √ | 8 wk, 4 and 6 mo, 1 y | ||
| √ | - | 2 and 8 wk, 4 and 6 mo | ||||||
| 7 | Mild | - | - | Yes | √ | - | - | 2 wk, 6 and 10 mo |
| 8 | - | Moderate | - | Yes | √ | - | - | 2 and 8 wk |
| 9 | - | Moderate | - | No | - | - | - | - |
| 10 | Mild | - | - | No | - | - | - | - |
| 11 | - | Moderate | - | No | - | - | - | - |
| 12 | Mild | - | - | No | - | - | - | - |
| 13 | Mild | - | - | No | - | - | - | - |
| 14 | Mild | - | - | No | - | - | - | - |
| 15 | Mild | - | - | No | - | - | - | - |
| Patients . | Marrow failure status at baseline . | Hematological response . | ANC response . | Hb response . | Platelet response . | Time of response . | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Mild | - | - | Yes | √ | - | - | 8 wk, 6 mo |
| 2 | - | - | Severe | Yes | √ | - | - | 2 and 8 wk, 4 mo |
| 3 | - | Moderate | - | Yes | √ | - | - | 2 and 8 wk, 4 mo |
| 4 | - | - | Severe | Yes | √ | - | - | 8 wk, 6 mo |
| 5 | Mild | - | - | Yes | - | - | √ | 4, 8, and 14 wk, 4, 6, and 9 mo, 1 y |
| 6 | Mild | - | - | Yes | √ | 8 wk, 4 and 6 mo, 1 y | ||
| √ | - | 2 and 8 wk, 4 and 6 mo | ||||||
| 7 | Mild | - | - | Yes | √ | - | - | 2 wk, 6 and 10 mo |
| 8 | - | Moderate | - | Yes | √ | - | - | 2 and 8 wk |
| 9 | - | Moderate | - | No | - | - | - | - |
| 10 | Mild | - | - | No | - | - | - | - |
| 11 | - | Moderate | - | No | - | - | - | - |
| 12 | Mild | - | - | No | - | - | - | - |
| 13 | Mild | - | - | No | - | - | - | - |
| 14 | Mild | - | - | No | - | - | - | - |
| 15 | Mild | - | - | No | - | - | - | - |
Marrow failure status was defined using standard clinical criteria. Mild: ANC <1500/μL, platelet count <150x109/L to 50x109/L, or Hb ≥8 to <11 g/dL. Moderate: ANC <1000/μL, platelet count <50x109/L, or Hb <8 g/dL. Severe: ANC <500/μL, platelet count <20x109/L, or Hb <8 g/dL. The lowest value of the 3 cell lineages defined the level of marrow failure. Hematological response to therapy was defined a priori as at least 1 of the following: increase in platelet count of >20x109/L over count at enrollment, observed on 2 consecutive occasions at least 2 weeks apart without transfusion; increase in Hb of at least 1 g/dL over level recorded at enrollment observed on 2 consecutive occasions at least 2 weeks apart without transfusion; and increase in ANC of at least 500/μL over level recorded at enrollment observed on 2 consecutive occasions at least 2 weeks apart. It should be noted that 3 patients (patients 5, 6, and 7) showed evidence of more sustained response in counts compared with the other patients in whom response was seen at limited time points.
-, not applicable; √, yes; Hb, hemoglobin.